<DOC>
	<DOCNO>NCT02478073</DOCNO>
	<brief_summary>Antibiotic dose critically ill patient pose challenge clinician due pharmacokinetic change see population . Piperacillin/tazobactam often use empirical treatment , initial appropriate dose crucial reduce mortality . Patients Intensive Care Unit ( ICU ) , treat piperacillin/tazobactam , plasma concentration piperacillin determine 1-3 time weekly . Patients receive piperacillin intermittent bolus infusion 3 time daily continuous infusion ( treat physician ) . Time minimal inhibitory concentration ( T &gt; MIC ) estimate patient evaluate clinical breakpoint MIC Pseudomonas aeruginosa ( 16 mg/L ) . Pharmacokinetic-pharmacodynamic ( PK-PD ) target evaluate 100 % f T &gt; MIC ( free piperacillin concentration maintain MIC throughout dose interval ) 50 % fT &gt; 4xMIC ( free piperacillin concentration maintain level fourfold MIC least 50 % dose interval ) .</brief_summary>
	<brief_title>Piperacillin Pharmacokinetics ICU Patients</brief_title>
	<detailed_description>Early appropriate antimicrobial therapy utmost importance reduce mortality critically ill patient sepsis septic shock . Pathophysiological change associate septic process , change volume distribution ( Vd ) , drug clearance ( CL ) , decrease plasma-protein concentration organ dysfunction , lead pharmacokinetic ( PK ) change may alter efficacy antimicrobial give . As consequence , antibiotic plasma concentration variable hard predict patient , make optimal antibiotic exposure challenge , especially early phase treatment . Piperacillin/tazobactam β-lactam - β-lactamase inhibitor combination frequently use empirical treatment critically ill . It time-dependent antibiotic antibacterial activity related time free , unbound concentration drug maintain minimal inhibitory concentration ( f T &gt; MIC ) . Maximizing f T &gt; MIC increase therapeutic impact reduces risk drug resistance development . Because PK change see critically ill , standard dose antimicrobial may result subtherapeutic plasma-concentrations suggest current empiric dosing recommendation Intensive Care Unit ( ICU ) patient inadequate need reconsider . Piperacillin/tazobactam generally administer either 4g/0.5g every 8 hour ( h ) 12g give continuously 24 hours.The aim study determine dose result therapeutic plasma concentration septic patient . Patients treat piperacillin/tazobactam give intermittent bolus infusion piperacillin plasma concentration determine week . Patients treat piperacillin/tazobactam give continuous infusion piperacillin plasma concentration determine three time week . Time minimal inhibitory concentration ( T &gt; MIC ) estimate patient evaluate clinical breakpoint MIC Pseudomonas aeruginosa ( 16 mg/L ) . Pharmacokinetic-pharmacodynamic ( PK-PD ) target evaluate 100 % f T &gt; MIC ( free piperacillin concentration maintain MIC throughout dose interval ) 50 % fT &gt; 4xMIC ( free piperacillin concentration maintain level fourfold MIC least 50 % dose interval ) . The unbound piperacillin plasma concentration determine use ultra high performance liquid chromatography ( UPLC ) . There intervention study .</detailed_description>
	<mesh_term>Shock , Septic</mesh_term>
	<mesh_term>Piperacillin</mesh_term>
	<criteria>Sepsis septic shock Treatment piperacillin/tazobactam Age 18 year Renal replacement therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>